FDA recall D-1386-2019

Fresenius Kabi USA, LLC · Class III · drug

Product

Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047, NDC 63323-374-20

Reason for recall

Failed Impurities/Degradation Specifications.

Distribution

Nationwide within the United States

Key facts

Status
Terminated
Initiation date
2019-05-22
Report date
2019-06-19
Termination date
2021-01-28
Voluntary/Mandated
Voluntary: Firm initiated
Location
Grand Island, NY, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1386-2019